Skip to main content
Signal8

Summit Therapeutics Inc. (SMMT)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Summit Therapeutics Inc. logo

Summit Therapeutics Inc.

NASDAQ:SMMTHealthcare
Pre-0.80%$16.20
Close$16.33+15.08%AH$16.30-0.61%since
Mkt Cap$13.06B
Float138.49M
O/S799.76M
PM VOL71K sh
$ Vol≈$1.15M
RVOL0.70×
Inst Own16.9%
SI29.5%
Dilution
Summit Therapeutics Inc. logoNASDAQ:SMMTPre$16.20-0.80%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202614.7916.3614.6616.335,795,790
Nov 5, 202616.1016.1214.1714.195,940,026
Nov 4, 202616.1516.4315.4116.174,258,105
Nov 3, 202614.9316.4214.8615.806,045,173
Nov 2, 202615.9916.0314.7414.803,870,034
Oct 30, 202616.0316.4315.5616.033,508,018
Oct 29, 202615.8016.5515.7516.204,415,071
Oct 28, 202615.1915.8015.0715.773,316,819
Oct 27, 202614.5415.3814.4015.334,739,591
Oct 26, 202615.4915.6214.3714.504,782,986
Oct 23, 202615.4615.5515.0715.473,210,684
Oct 22, 202615.2915.7015.1315.554,150,761
Oct 21, 202616.3516.3515.7215.835,366,558
Oct 20, 202615.5016.1815.0616.096,252,801
Oct 19, 202614.9015.7714.8315.576,154,201
Oct 16, 202615.3915.4114.5614.634,331,009
Oct 15, 202615.0915.5515.0815.374,733,234
Oct 14, 202615.2915.5615.0415.134,661,711
Oct 13, 202616.7916.7915.4615.527,131,982
Oct 12, 202617.4817.5917.0517.134,375,907
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
14
HOLD
7
SELL
0
TOTAL21
Insider Trades
InsiderTypeShares
Anand Bhaskar profile photoAnand BhaskarGrant/Award100.0K
Zanganeh Mahkam profile photoZanganeh MahkamPurchase3.81M
DUGGAN ROBERT W profile photoDUGGAN ROBERT WPurchase3.81M
Soni Manmeet Singh profile photoSoni Manmeet SinghPurchase25.0K
Soni Manmeet Singh profile photoSoni Manmeet SinghPurchase25.0K
DUGGAN ROBERT W profile photoDUGGAN ROBERT WPurchase100.0K
Shareholders
16.9%
Institutional
(269)
72.2%
Insiderⓘ
(4)
0.0%
5%+ Owners
(0)
10.9%
Unattributed (incl. retail)ⓘ
Institutional16.9%
Insider72.2%
Unattributed (incl. retail)10.9%
Sources: 13F, Form 4, 13D/13GO/S: 799.8M · as of 30 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America.

The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI).

Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE).

Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Key Metrics
Market Cap$13.06B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership16.95%

based on 799.76M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateMar 5, 2015
Shares Outstanding799.76M
Authorized Shares
Float138.49M
52-Week Range
$12.07$29.23
$16.33(25th percentile)
Volume
Average Daily Volume4.85M
5.80M today vs 4.85M avg(+19%)

30d Avg

4.85M

60d Avg

6.18M

90d Avg

6.30M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...